Ligand Pharmaceuticals Incorporated Share Price Today: Live Updates & Key Insights

Ligand Pharmaceuticals Incorporated share price today is $204.75, up -2.7%. The stock opened at $211.41 against the previous close of $210.49, with an intraday high of $212.84 and low of $204.655.

Ligand Pharmaceuticals Incorporated Share Price Chart

Ligand Pharmaceuticals Incorporated

us-stock
To Invest in {{usstockname}}
us-stock

Ligand Pharmaceuticals Incorporated Share Price Performance

$204.75 -0.027(-2.7%) LGND at 23 Mar 2026 01:57 PM Biotechnology
Lowest Today 204.655
Highest Today 212.84
Today’s Open 211.41
Prev. Close 210.49
52 Week High 227.92
52 Week Low 93.58
Day’s Range: Low 204.655 High 212.84
52-Week Range: Low 93.58 High 227.92
1 day return -
1 Week return -0.74
1 month return +12.75
3 month return +4.3
6 month return +20.52
1 year return +84.81
3 year return +205.07
5 year return +101.17
10 year return -

Ligand Pharmaceuticals Incorporated Institutional Holdings

Tudor Investment Corp Et AL 78.98

BlackRock Inc 14.47

Vanguard Group Inc 10.40

iShares Core S&P Small-Cap ETF 5.99

HHG PLC 5.23

Macquarie Group Ltd 3.77

State Street Corp 3.76

Vanguard Total Stock Mkt Idx Inv 2.96

FMR Inc 2.90

Chicago Capital LLC 2.82

Janus Henderson Triton D 2.66

Janus Henderson US SMID Cap Growth 2.66

Massachusetts Financial Services Company 2.54

Stephens Inv Mgmt Group LLC 2.51

Geode Capital Management, LLC 2.48

Congress Asset Management Company, LLP 2.41

iShares Russell 2000 ETF 2.35

Franklin DynaTech Fund A 2.26

Franklin Innovation Composite 2.26

Dimensional Fund Advisors, Inc. 2.17

Vanguard Small Cap Index 2.12

Nomura Small Cap Core I 2.09

Loomis, Sayles & Company LP 1.92

Fidelity Small Cap Value Fund 1.91

Amvescap Plc. 1.90

UBS Asset Mgmt Americas Inc 1.89

The Goldman Sachs Group Inc 1.84

Stephens SMID Select Growth 1.74

Deutsche Bank AG 1.54

Rice Hall James & Associates, LLC 1.40

Vanguard Small Cap Value Index Inv 1.36

Congress Small Cap Growth Institutional 1.36

Ranger Investment Management LP 1.35

Janus Henderson US Small Cap Growth 1.35

Janus Henderson Venture D 1.35

Invesco Discovery A 1.35

Vanguard Explorer Inv 1.34

DWS Small Cap Core S 1.30

Small Cap Core Equity Composite 1.30

MFS New Discovery I 1.21

Ligand Pharmaceuticals Incorporated Market Status

Strong Buy: 4

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Ligand Pharmaceuticals Incorporated Fundamentals

Market Cap 4084.14 M

PB Ratio 4.015

PE Ratio 33.4657

Enterprise Value 3779.32 M

Total Assets 1560.64 M

Volume 468277

Ligand Pharmaceuticals Incorporated Company Financials

Annual Revenue FY25:268087000 268.1M, FY23:153595000 153.6M, FY22:196245000 196.2M, FY21:277133000 277.1M, FY20:186419000 186.4M

Annual Profit FY25:null 0.0M, FY23:123110000 123.1M, FY22:143418000 143.4M, FY21:214957000 215.0M, FY20:156000000 156.0M

Annual Net worth FY25:124453000 124.5M, FY23:16481000 16.5M, FY22:-5219000 -5.2M, FY21:57586000 57.6M, FY20:-2985000 -3.0M

Quarterly Revenue Q4/2025:59666000 59.7M, Q3/2025:115461000 115.5M, Q2/2025:47627000 47.6M, Q1/2025:45333000 45.3M, Q3/2024:51812000 51.8M

Quarterly Profit Q4/2025:null 0.0M, Q3/2025:90641000 90.6M, Q2/2025:44720000 44.7M, Q1/2025:40484000 40.5M, Q3/2024:39317000 39.3M

Quarterly Net worth Q4/2025:44784000 44.8M, Q3/2025:117273000 117.3M, Q2/2025:4847000 4.8M, Q1/2025:-42451000 -42.5M, Q3/2024:-7172000 -7.2M

About Ligand Pharmaceuticals Incorporated & investment objective

Company Information Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Organisation Biotechnology

Employees 47

Industry Biotechnology

CEO Mr. Todd C. Davis Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Ligand Pharmaceuticals Incorporated FAQs

What is the share price of Ligand Pharmaceuticals Incorporated today?

The current share price of Ligand Pharmaceuticals Incorporated is $204.75.

Can I buy Ligand Pharmaceuticals Incorporated shares in India?

Yes, Indian investors can buy Ligand Pharmaceuticals Incorporated shares by opening an international trading and demat account with Motilal Oswal.

How to buy Ligand Pharmaceuticals Incorporated shares in India?

You can easily invest in Ligand Pharmaceuticals Incorporated shares from India by:

Can I buy fractional shares of Ligand Pharmaceuticals Incorporated?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated has a market cap of $4084.14 M.

In which sector does Ligand Pharmaceuticals Incorporated belong?

Ligand Pharmaceuticals Incorporated operates in the Biotechnology sector.

What documents are required to invest in Ligand Pharmaceuticals Incorporated stocks?

To invest, you typically need:

What is the PE and PB ratio of Ligand Pharmaceuticals Incorporated?

The PE ratio of Ligand Pharmaceuticals Incorporated is 33.47 and the PB ratio is 4.02.